Kymera Therapeutics Inc (KYMR) reports robust financial health and strategic advancements, setting the stage for significant ...
Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...
Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and ChinaTopline ...
Novavax (NASDAQ:NVAX) shares traded marginally higher on Thursday in the premarket after the Gaithersburg, Maryland-based ...
Q4 2024 Earnings Call Transcript February 26, 2025 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is ...
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported ...
An FDA advisory committee meeting scheduled next month to decide the composition of next season’s flu vaccines has been ...
The Trump administration will allocate up to $1B to prevent the spread of bird flu and boost egg imports, Reuters reported, ...
Investing News Network on MSN2d
Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...
Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar ...
On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback